Progress of PARP inhibitors in targeted therapy of small cell lung cancer / 国际肿瘤学杂志
Journal of International Oncology
; (12): 368-372, 2023.
Article
in Zh
| WPRIM
| ID: wpr-989573
Responsible library:
WPRO
ABSTRACT
Small cell lung cancer (SCLC) is a rapidly developing malignant tumor, which is highly heterogeneous and prone to drug resistance, and the prognosis is usually poor. Poly ADP-ribose polymerase (PARP) inhibitors target the DNA damage response pathway, preventing DNA repair, thereby exerting anti-tumor effects. Currently, PARP inhibitors are used as monotherapy or in combination with DNA-damaging agents or immune checkpoint inhibitors in the treatment of SCLC. Although the current research results are limited, it can be seen that PARP inhibitors may be a breakthrough in the targeted therapy of SCLC.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Journal of International Oncology
Year:
2023
Type:
Article